Physician profile
Steven Daniel
NPI 1245420108
$21,572.04
in general payments reported to CMS, 2019-2025
65 companies · $3,301 in 2025
The $3,301 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,571 · 2020: $2,551 · 2021: $3,254 · 2022: $3,079 · 2023: $3,209 · 2024: $2,608 · 2025: $3,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,045 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,044.74 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,847.16 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,284.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,845.67 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $1,820.55 | 2019-2025 | Ubrelvy, Synthroid, Vraylar |
| Lilly USA, LLC | $1,589.17 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $1,101.85 | 2019-2025 | Xarelto, Spravato |
| Amarin Pharma, INC. | $991.07 | 2019-2023 | |
| Amgen INC. | $990.68 | 2019-2025 | Repatha, Otezla, Repatha |
| Amneal Pharmaceuticals LLC | $629.26 | 2019-2025 | Unithroid, Crexont |
| Glaxosmithkline, LLC. | $533.90 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Antares Pharma, INC. | $493.88 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $422.44 | 2019-2025 | |
| Corium, LLC | $383.09 | 2022-2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $371.81 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $340.29 | 2019-2025 | Xifaxan |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.